The company manufactures and exports textile fabrics and garments while also operating a large-scale distribution business for international cosmetic and personal care brands across India.
The company lacks a durable moat; while it has established distribution relationships for global FMCG brands, these are contractual rather than proprietary. The textile segment operates in a highly commoditized market, and the overall business shows low cash conversion (0.48) despite decent accounting margins.
Management prioritizes reinvestment into working capital and maintains a very low debt profile. However, significant funds are tied up in related-party transactions and advances, and dividend payouts are inconsistent, with a total skip in FY25 to conserve cash.
The business collapsed as the gap between accounting profits and actual cash flow became an unbridgeable chasm. While the income statement showed growth, the capital was perpetually trapped in related-party advances and stagnant working capital. Eventually, the global FMCG brands exercised their contractual right to bypass the middleman, and the commoditized textile arm could not cover the overhead. The promoters, having already prioritized their own entities through extensive related-party transactions, left minority shareholders holding a shell of a business with no cash and no remaining distribution rights.
RichFakir rates M K Exim (India) Ltd's business quality as mediocre — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, M K Exim (India) Ltd is trading about 37% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on M K Exim (India) Ltd is: Not rated. A mediocre business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of M K Exim (India) Ltd's fair value is about ₹84 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →